Healthy Outcome under Olanzapine Treatment in a Pregnant Woman

 

 Buy Article Permissions and Reprints

Our report focuses on the case of a pregnant women with recurrent, paranoid schizophrenia. The patient was treated with Olanzapine from the 18^th gestational week until delivery and during breast-feeding. No adverse events occurred during pregnancy, and the outcome was healthy. After delivery, the plasma level of olanzapine in the infant was one-third of the maternal plasma level, and during breast-feeding, it decreased to an undetectable limit.

References

• 1 Altshuler L L, Cohen L, Szuba M P, Burt V K, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines.  Am. J. Psychiatr.. 1996;  153 -606
  PubMedGoogle Scholar
• 2 Ananth J. Side effects in the neonate from psychotropic agents excreted through breast-feeding.  Am. J. Psychiatr.. 1978;  135 -805
  PubMedGoogle Scholar
• 3 Brazelton T B. Effect of perinatal drugs on the behaviour of the neonate.  Am. J. Psychiatr.. 1970;  126 1261-1266
  PubMedGoogle Scholar
• 4 Cohen L S, Rosenbaum J F. Psychotropic drug use during pregnancy: weighing the risks.  J. Clin. Psychiatry.. 1998;  59 (suppl. 2) 18-28
  PubMedGoogle Scholar
• 5 Crawford A MK, Beasley C M Jr, Tollefson G D. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.  Schiz. Res.. 1997;  26 41-54
  PubMedGoogle Scholar
• 6 Dickson R A, Dawson D T. Olanzapine and pregnancy.  Can. J. Psychiat.. 1998;  43 196-197
  PubMedGoogle Scholar
• 7 Dieulangard P, Coignet J, Vical J C. Sur un cas d'ectro-phocome¿lie, peut-tre d'origine medicamenteuse (On a case of congenital dwarfism, perhaps of the origin of medication) Bull.  Lippincott-Raven publishers.. 1966;  18 85-87
  PubMedGoogle Scholar
• 8 Edlund M J, Craig T J. Antipsychotic drug use and birth defects: an epidemiologic reassessment.  Compr. Psychiat.. 1984;  25 32-37
  CrossrefPubMedGoogle Scholar
• 9 Hagopian G S, Meyers D B, Markham J K. Teratology studies of LY170053 in rats and rabits.  Teratology.. 1987;  35 60
  PubMedGoogle Scholar
• 10 Hanson G, Oakley G, Ruddock V M, Townsend J, Meade T W. Haloperidol and limb deformity (letter).  JAMA. 1975;  231 26
  CrossrefPubMedGoogle Scholar
• 11 Koren G, Pastuszak A, Shinya I. Drugs in pregnancy.  N. Engl. J. Med.. 1998;  338 1128-1137
  CrossrefPubMedGoogle Scholar
• 12 Liebermann J, Safferman A Z. Clinical profile of clozapine: adverse reactions and agranulozytosis. In: Clozapine in treatment resistant schizophrenia: a scientific update. Lapierre Y., J.B. London (eds.) Royal Society of Medicine 1992
  Google Scholar
• 13 McCollan F W, Heggeness L. Limb malformations following maternal use of haloperidol.  JAMA. 1975;  231 62-64
  CrossrefPubMedGoogle Scholar
• 14 Meltzer F Y, Goode D J, Schyve P M, Young M, Fang V S. Effect of clozapine on human serum prolactin levels.  Am. J. Psychiat.. 1979;  136 1550-1555
  PubMedGoogle Scholar
• 15 Milkovich L, Van den Berg B J. An evaluation of the teratogenicity of certain antinauseant drugs.  Am. J. Obstet. Gynecol.. 1976;  125 -248
  PubMedGoogle Scholar
• 16 Orr S, Miller C. Maternal depressive symptoms and the risk of poor pregnancy outcome: review of the literature and preliminary findings.  Epidemiol. Rev.. 1995;  17(1) 165-171
  PubMedGoogle Scholar
• 17 Patel A J, Barochovsky O, Lewis P D. Psychotropic drugs and brain development: effects on cell replication in vivo and in vitro.  Neuropharmacol.. 1981;  20 1243-1249
  PubMedGoogle Scholar
• 18 Perkin M R, Bland J M, Peacock J L. The effect of anxiety and depression during pregnancy on obstetric complications.  Br. J. Obstet. Gynaecol.. 1993;  100 629-634
  PubMedGoogle Scholar
• 19 Rieder R O, Rosenthal D, Wender P, Blumenthal H. The offspring of schizophrenics. Fetal and neonatal deaths.  Arch. Gen. Psychiat.. 1975;  32 200-211
  PubMedGoogle Scholar
• 20 Rumeau-Rouquette C, Goujard J, Huel C. Possible teratogenic effects of phenothiazines in human beings.  Teratology.. 1977;  15 57-64
  CrossrefPubMedGoogle Scholar
• 21 Slone D, Suskind V, Heinonen O P, Monson R R, Kaufman D W, Shapiro S. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality, birth weight and intelligence quotient score.  Am. J. Obstet. Gynecol.. 1977;  128 -488
  PubMedGoogle Scholar
• 22 Steer R A, Scholl T O, Hediger M L, Fischer R L. Self-reported depression and negative pregnancy outcomes.  J. Clin. Epidemiol.. 1992;  45 1093-1099
  CrossrefPubMedGoogle Scholar
• 23 Stoner S C, Sommi R W jr, Marken P A, Anya I, Vaughn. Clozapine use in two full-term pregnancies.  J. Clin. Psychiatr.. 1997;  58 364-365
  PubMedGoogle Scholar
• 24 Tenyi T, Trixler M, Vereczkey G, Dorka A. (Use of clozapine during pregnancy) Clozapine alkalmazasarol terhesseg soran.  Orv. Hetil.. 1994;  135 1967-1969
  PubMedGoogle Scholar
• 25 Thiels C. Pharmacotherapy of psychiatric disorder in pregnancy and during breastfeeding: a review.  Pharmacopsychiat.. 1987;  20 133-146
  PubMedGoogle Scholar
• 26 Van Waes A, Van de Velde E. Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum.  J. Clin. Pharmacol.. 1969;  9 -226
  PubMedGoogle Scholar
• 27 Waldman M, Saffermann A. Pregnancy and clozapine.  Am. J. Psychiatry.. 1993;  150 168-169
  PubMedGoogle Scholar
• 28 Zuckerman B, Bauchner H, Parker S, Cabral H. Maternal depressive symptoms during pregnancy and newborn irritability.  J. Dev. Behav. Pediatr.. 1990;  11 (8) 190-194
  PubMedGoogle Scholar

MD Julia Kirchheiner,

Institut für Klinische Pharmakologie Universitätsklinikum Charité Humboldt-Universität zu Berlin

Schumannstraße 20-21

D-10098 Berlin

Germany